MCID: HMS001
MIFTS: 50

Hemosiderosis

Categories: Rare diseases, Metabolic diseases

Aliases & Classifications for Hemosiderosis

MalaCards integrated aliases for Hemosiderosis:

Name: Hemosiderosis 12 72 49 51 41 14 69
Iron Overload 41 69
Haemosiderosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12119
NCIt 46 C82892
SNOMED-CT 64 190849009 39011001

Summaries for Hemosiderosis

Disease Ontology : 12 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary : Hemosiderosis, also known as iron overload, is related to iron overload in africa and aceruloplasminemia. An important gene associated with Hemosiderosis is TF (Transferrin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Insulin receptor recycling. The drugs Deferasirox and Iron have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and heart, and related phenotypes are hematopoietic system and liver/biliary system

Wikipedia : 72 Hemosiderosis (AmE) or haemosiderosis (BrE) is a form of iron overload disorder resulting in the... more...

Related Diseases for Hemosiderosis

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 iron overload in africa 34.5 HFE TF
2 aceruloplasminemia 31.4 CP FTL TF
3 atransferrinemia 30.0 CP HAMP HFE SLC11A2 SLC40A1 TF
4 thalassemia 29.5 EPO HFE TF TFRC
5 hemoglobin h disease 29.5 EPO TF TFRC
6 liver cirrhosis 29.3 GPT HFE TF
7 microcytic anemia 28.8 EPO SLC11A2 TF TFRC
8 siderosis 28.8 HFE SLC40A1 TF TFRC
9 porphyria cutanea tarda 28.7 HAMP HFE TF TFRC
10 beta-thalassemia 28.5 EPO HAMP HFE TF TFRC
11 iron metabolism disease 28.1 CP EPO HFE SLC11A2 SLC40A1 TF
12 iron deficiency anemia 27.8 EPO HAMP HFE SLC11A2 SLC40A1 TF
13 hemochromatosis, type 1 26.6 CP FTL HAMP HFE SLC11A2 SLC40A1
14 deficiency anemia 26.6 CP EPO FTL HAMP HFE SLC11A2
15 hypochromic microcytic anemia with iron overload 12.6
16 anemia, hypochromic microcytic, with iron overload 1 12.5
17 pulmonary hemosiderosis 12.5
18 anemia, hypochromic microcytic, with iron overload 2 12.5
19 hemochromatosis, type 5 12.2
20 secondary pulmonary hemosiderosis 12.0
21 hemosiderosis, pulmonary, with deficiency of gamma-a globulin 11.9
22 superficial siderosis 11.6
23 gracile syndrome 11.1
24 fascioliasis 10.3 CP GPT
25 ancylostomiasis 10.3 CP TF
26 hfe-associated hereditary hemochromatosis 10.3 HFE SLC11A2
27 swayback 10.3 CP HFE
28 kwashiorkor 10.3 GPT TF
29 eales disease 10.2 CP TF
30 hepatitis 10.2
31 epileptic encephalopathy, early infantile, 36 10.2 CP TF
32 nonalcoholic steatohepatitis 10.2 GPT HFE
33 pure red-cell aplasia 10.1 EPO TF
34 celiac disease 1 10.1
35 hypochromic microcytic anemia 10.1 CP SLC11A2 TF
36 protein-energy malnutrition 10.1 CP GPT TF
37 angiomatous meningioma 10.1 TF TFRC
38 hemorrhagic fever 10.1 GPT TFRC
39 fetal erythroblastosis 10.1 EPO TFRC
40 analbuminemia 10.0 EPO GPT TF
41 vitamin b12 deficiency 10.0 EPO GPT TF
42 fibrosis of extraocular muscles, congenital, 1 10.0
43 glomerulonephritis 10.0
44 cerebritis 10.0
45 anemia of prematurity 9.9 EPO HAMP
46 heart disease 9.9
47 rhizomelic chondrodysplasia punctata, type 2 9.9 HAMP HFE
48 inherited metabolic disorder 9.9 HAMP HFE TF
49 folic acid deficiency anemia 9.9 EPO TF TFRC
50 restless legs syndrome 9.9 EPO SLC11A2 TFRC

Graphical network of the top 20 diseases related to Hemosiderosis:



Diseases related to Hemosiderosis

Symptoms & Phenotypes for Hemosiderosis

MGI Mouse Phenotypes related to Hemosiderosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CP EPO HFE SLC11A2 SLC40A1 TF
2 liver/biliary system MP:0005370 9.1 CP EPO HFE SLC11A2 SLC40A1 TFRC

Drugs & Therapeutics for Hemosiderosis

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3 201530-41-8 5493381
2
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
3
Deferiprone Approved Phase 4,Phase 2,Phase 3 30652-11-0 2972
4
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3 70-51-9 2973
5
Metformin Approved Phase 4 657-24-9 4091 14219
6 Chelating Agents Phase 4,Phase 2,Phase 3
7 Iron Chelating Agents Phase 4,Phase 2,Phase 3
8 Micronutrients Phase 4,Phase 2,Phase 3
9 Trace Elements Phase 4,Phase 2,Phase 3
10 Liver Extracts Phase 4,Phase 2,Phase 3
11 Hypoglycemic Agents Phase 4
12
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 10883523 5280795 6221
13
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
15 Epoetin alfa Phase 2 113427-24-0
16 Hematinics Phase 2
17 Bone Density Conservation Agents Phase 2
18 Calcium, Dietary Phase 2
19 Ergocalciferols Phase 2
20 Vitamins Phase 2
21 Calciferol Nutraceutical Phase 2
22 Vitamin D2 Nutraceutical Phase 2
23
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
24 tannic acid Approved, Nutraceutical

Interventional clinical trials:

(show all 38)

# Name Status NCT ID Phase Drugs
1 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4 Deferasirox
2 Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4 deferasirox:
3 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
4 ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox Completed NCT00466063 Phase 4 Deferasirox
5 Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
6 Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload Completed NCT00654589 Phase 4 Deferasirox
7 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
8 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
9 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Not yet recruiting NCT03372083 Phase 4 Deferasirox
10 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
11 Safety, Tolerability, and Efficacy of Deferasirox in MDS Completed NCT00469560 Phase 3 Deferasirox
12 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3 deferasirox
13 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions Completed NCT00061750 Phase 3 ICL670;deferoxamine
14 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
15 Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis Completed NCT00631163 Phase 2 Deferasirox (ICL670)
16 Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions Completed NCT00067080 Phase 2 ICL670, deferoxamine
17 Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Completed NCT00600938 Phase 2 Core Study: Deferasirox;Core Study: Deferoxamine;Extension: deferoxamine to deferasirox;Extension: deferasirox to deferoxamine;Deferasirox;Deferoxamine
18 Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients Completed NCT00303329 Phase 2 Deferasirox
19 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed NCT00061763 Phase 2 Deferasirox
20 Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). Completed NCT01090323 Phase 2 ICL670
21 Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) Completed NCT02428686 Phase 2 Epoetin beta (NeoRecormon)
22 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
23 The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) Not yet recruiting NCT02854722 Phase 2 Deferasirox and calcium-vitamin D3;Calcium-vitamin D3
24 Treatment of Iron Overload Requiring Chelation Therapy Withdrawn NCT01927913 Phase 2 SPD602;Deferasirox
25 Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease Completed NCT02434718 Phase 1 Aducanumab;Placebo
26 PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood Unknown status NCT00652964
27 Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox Completed NCT01394029 deferasirox
28 Pharmacogenetic Study in Patients Received Iron Chelating Agent Completed NCT01623895
29 Non-invasive Quantification of Liver Iron With MRI Completed NCT01516853
30 Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease Completed NCT02394431
31 The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? Completed NCT02837354
32 Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content Recruiting NCT02025543
33 Red Blood Cell Transfusion Thresholds and QOL in MDS Recruiting NCT02099669
34 A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients. Enrolling by invitation NCT01935661
35 Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter Enrolling by invitation NCT00481221
36 Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis Not yet recruiting NCT02985346 Early Phase 1
37 Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis Not yet recruiting NCT02664571
38 Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox Not yet recruiting NCT03358498

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: hemosiderosis

Genetic Tests for Hemosiderosis

Anatomical Context for Hemosiderosis

MalaCards organs/tissues related to Hemosiderosis:

38
Liver, Lung, Heart, Bone, Bone Marrow, Kidney, Brain

Publications for Hemosiderosis

Articles related to Hemosiderosis:

(show top 50) (show all 1090)
# Title Authors Year
1
The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature. ( 29332607 )
2018
2
A composite mouse model of aplastic anemia complicated with iron overload. ( 29434729 )
2018
3
Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. ( 29371322 )
2018
4
Hereditary hypochromic microcytic anemia associated with loss-of-function DMT1 gene mutations and absence of liver iron overload. ( 29178181 )
2018
5
Correlation of Pancreatic Iron Overload Measured by T2*-Weighted Magnetic Resonance Imaging in Diabetic Patients with I^-Thalassemia Major. ( 28762844 )
2017
6
SERUM FERRITIN CONCENTRATION IS NOT A RELIABLE BIOMARKER OF IRON OVERLOAD DISORDER PROGRESSION OR HEMOCHROMATOSIS IN THE SUMATRAN RHINOCEROS (DICERORHINUS SUMATRENSIS). ( 28920821 )
2017
7
Methylprednisolone pulse therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis. ( 28784257 )
2017
8
Screening for hemosiderosis in patients receiving multiple red blood cell transfusions. ( 28129458 )
2017
9
Idiopathic pulmonary hemosiderosis: Hemorrhagic flare after 6 years of remission. ( 28844597 )
2017
10
Welder's pulmonary hemosiderosis associated with systemic iron overload following exacerbation of acute adult T-cell leukemia/lymphoma. ( 28883221 )
2017
11
Auricular Hemosiderosis in a Diabetic Patient. ( 28859747 )
2017
12
Epilepsy caused by superficial hemosiderosis of the central nervous system. ( 29105005 )
2017
13
Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. ( 28460338 )
2017
14
Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. ( 28456904 )
2017
15
Identification of new BMP6 pro-peptide mutations in patients with iron overload. ( 28335084 )
2017
16
Idiopathic Pulmonary Hemosiderosis Mimicking Iron Deficiency Anemia: A Delayed Diagnosis? ( 28670434 )
2017
17
Corticosteroid in combination with leflunomide and mesenchymal stem cells for treatment of pediatric idiopathic pulmonary hemosiderosis. ( 28158572 )
2017
18
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. ( 28642302 )
2017
19
Hemochromatosis Protein (HFE) Knockout Mice As a Novel Model of Hemochromatosis: Implications for Study and Management of Iron-Overload Cardiomyopathy. ( 28558947 )
2017
20
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis. ( 28067690 )
2017
21
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. ( 28482720 )
2017
22
A Case of Idiopathic Pulmonary Hemosiderosis Presenting With Signs and Symptoms Mimicking Hemolytic Anemia. ( 27918350 )
2017
23
Renal Hemosiderosis among Iranian Transfusion Dependent I^-Thalassemia Major Patients. ( 28875008 )
2017
24
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). ( 28296163 )
2017
25
Idiopathic Pulmonary Hemosiderosis in a Child with Recurrent Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis. ( 28251009 )
2017
26
Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia. ( 28707012 )
2017
27
Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. ( 28866669 )
2017
28
Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis. ( 28720890 )
2017
29
Clinical and Laboratory Associations with Persistent Hyperferritinemia in 373 Black Hemochromatosis and Iron Overload Screening Study Participants. ( 28809726 )
2017
30
HFE gene mutation and iron overload in Egyptian pediatric acute lymphoblastic leukemia survivors: a single-center study. ( 28211293 )
2017
31
Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. ( 28815805 )
2017
32
The hepatocyte-specific HNF4I+/miR-122 pathway contributes to iron overload-mediated hepatic inflammation. ( 28655781 )
2017
33
Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. ( 26908385 )
2016
34
Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major. ( 27548334 )
2016
35
Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A. ( 27383256 )
2016
36
Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis. ( 27013087 )
2016
37
Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran. ( 26838079 )
2016
38
Iron Overload Leading to Torsades de Pointes in I^-Thalassemia and Long QT Syndrome. ( 26920202 )
2016
39
Frequency of Hereditary Hemochromatosis (HFE) Gene Mutations in Egyptian Beta Thalassemia Patients and its Relation to Iron Overload. ( 27335591 )
2016
40
Hereditary hemochromatosis: Dealing with iron overload. ( 27032055 )
2016
41
Effect of the Hemochromatosis Mutations on Iron Overload among the Indian I^ Thalassemia Carriers. ( 27561698 )
2016
42
Proteomic Profiling of Iron Overload-Induced Human Hepatic Cells Reveals Activation of TLR2-Mediated Inflammatory Response. ( 26999096 )
2016
43
Glutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major. ( 26288192 )
2016
44
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. ( 27106071 )
2016
45
Comparison of Tissue Elastography With Magnetic Resonance Imaging T2star and Serum Ferritin Quantification in Detecting Liver Iron Overload in Patients With in Thalassemia Major. ( 27650324 )
2016
46
Helicobacter pylori Associated With Pulmonary Hemosiderosis. ( 26741588 )
2016
47
Unusual presentation: Concurrent IgA deficiency and idiopathic pulmonary hemosiderosis. ( 27120139 )
2016
48
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone. ( 27789107 )
2016
49
Effect of Hereditary Hemochromatosis Gene (HFE) H63D and C282Y Mutations on Iron Overload in Sickle Cell Disease Patients. ( 27095682 )
2016
50
Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. ( 26405152 )
2016

Variations for Hemosiderosis

Expression for Hemosiderosis

Search GEO for disease gene expression data for Hemosiderosis.

Pathways for Hemosiderosis

Pathways related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 CP FTL SLC11A2 SLC40A1 TF TFRC
2
Show member pathways
12.08 CP FTL SLC11A2 SLC40A1 TF TFRC
3 11.63 EPO TF TFRC
4
Show member pathways
11.59 CP SLC11A2 SLC40A1
5 11.44 CP EPO TF TFRC
6 11.27 FTL SLC11A2 SLC40A1 TF
7 11.18 EPO TF
8 11.01 EPO SLC11A2
9 10.7 CP FTL SLC11A2 SLC40A1 TF TFRC
10 10.43 HAMP SLC11A2 SLC40A1 TF TFRC
11 10.21 HAMP HFE

GO Terms for Hemosiderosis

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CP EPO FTL HAMP TF TFRC
2 extracellular space GO:0005615 9.8 CP EPO GPT HAMP HFE TF
3 cytoplasmic vesicle GO:0031410 9.78 HFE SLC11A2 TF TFRC
4 perinuclear region of cytoplasm GO:0048471 9.76 HFE SLC11A2 TF TFRC
5 cell surface GO:0009986 9.71 EPO SLC11A2 TF TFRC
6 early endosome GO:0005769 9.62 HFE SLC11A2 TF TFRC
7 endosome membrane GO:0010008 9.61 SLC11A2 TF TFRC
8 clathrin-coated pit GO:0005905 9.54 TF TFRC
9 blood microparticle GO:0072562 9.54 CP TF TFRC
10 extracellular vesicle GO:1903561 9.52 SLC11A2 TFRC
11 clathrin-coated vesicle membrane GO:0030665 9.51 TF TFRC
12 recycling endosome GO:0055037 9.46 HFE SLC11A2 TF TFRC
13 basal part of cell GO:0045178 9.13 HFE SLC11A2 TF
14 HFE-transferrin receptor complex GO:1990712 8.8 HFE TF TFRC

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.89 CP HFE SLC11A2 SLC40A1 TF
2 acute-phase response GO:0006953 9.61 EPO HAMP HFE
3 transferrin transport GO:0033572 9.58 HFE TF TFRC
4 iron ion transport GO:0006826 9.56 FTL SLC11A2 SLC40A1 TF
5 liver regeneration GO:0097421 9.55 HAMP HFE
6 positive regulation of receptor-mediated endocytosis GO:0048260 9.54 HFE TF
7 response to vitamin A GO:0033189 9.52 EPO HAMP
8 copper ion transport GO:0006825 9.51 CP SLC11A2
9 response to iron ion GO:0010039 9.5 HAMP HFE SLC11A2
10 cellular response to iron ion GO:0071281 9.48 HFE TF
11 iron ion transmembrane transport GO:0034755 9.46 SLC11A2 SLC40A1
12 multicellular organismal iron ion homeostasis GO:0060586 9.46 HAMP HFE SLC11A2 SLC40A1
13 response to iron ion starvation GO:1990641 9.37 HAMP HFE
14 iron ion homeostasis GO:0055072 9.35 FTL HFE SLC11A2 SLC40A1 TF
15 cellular iron ion homeostasis GO:0006879 9.23 CP FTL HAMP HFE SLC11A2 SLC40A1

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ferric iron binding GO:0008199 9.26 FTL TF
2 transferrin receptor binding GO:1990459 9.16 HFE TF
3 iron ion transmembrane transporter activity GO:0005381 8.96 SLC11A2 SLC40A1
4 ferrous iron transmembrane transporter activity GO:0015093 8.62 SLC11A2 SLC40A1

Sources for Hemosiderosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....